Female Infertility Market Report 2026

Female Infertility Market Overview

• Female Infertility market size has reached to $1.86 billion in 2025 • Expected to grow to $2.26 billion in 2030 at a compound annual growth rate (CAGR) of 3.8% • Growth Driver: Rising Infertility Trends Driving Demand For Advanced Treatments • Market Trend: Technological Advancements In Market With Non-Invasive Diagnostic Tests • Europe was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Female Infertility Market?

Female infertility is defined as the inability of a woman to conceive after 12 months of regular, unprotected sexual intercourse (or 6 months for women aged 35 or older) or the inability to carry a pregnancy to term. It is a complex condition resulting from various factors affecting the reproductive system. The main treatments for female infertility include clomiphene citrate, gonadotropins, metformin, letrozole, and bromocriptine. Clomiphene citrate is a medication commonly used to treat female infertility by stimulating ovulation. It can be administered through various routes, such as oral, parenteral, and others, and is used by hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Female Infertility Market Growth Forecast?

The female infertility market size is expected to see steady growth in the next few years. It will grow to $2.26 billion in 2030 at a compound annual growth rate (CAGR) of 3.8%. The growth in the forecast period can be attributed to advancements in fertility drug formulations, growth in personalized fertility treatments, increased adoption of AI-based fertility tracking, expansion of fertility tourism, rising investment in reproductive health. Major trends in the forecast period include rising demand for assisted reproductive treatments, increased focus on hormonal and ovulation therapies, growing use of advanced diagnostic techniques, expansion of fertility clinics and services, integration of digital platforms in fertility care.

Global Female Infertility Market Segmentation

1) By Treatment: Clomiphene Citrate, Gonadotropins, Metformin, Letrozole, Bromocriptine 2) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations 3) By End-User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy Subsegments: 1) By Clomiphene Citrate: Oral Clomiphene Citrate, Injectable Clomiphene Citrate 2) By Gonadotropins: Recombinant Gonadotropins, Urinary Gonadotropins, Human Chorionic Gonadotropin (hCG) 3) By Metformin: Immediate-Release Metformin, Extended-Release Metformin 4) By Letrozole: Oral Letrozole Tablets, Injectable Letrozole 5) By Bromocriptine: Oral Bromocriptine Tablets, Intranasal Bromocriptine

What Is The Driver Of The Female Infertility Market?

The increasing prevalence of infertility is expected to propel the growth of the female infertility market going forward. Infertility is the inability to conceive after 12 months of regular, unprotected sexual intercourse. Increasing infertility is driven by factors such as delayed childbearing, lifestyle changes, environmental toxins, rising obesity, and higher stress levels. Female infertility treatment is required to address and manage underlying medical, hormonal, or structural issues that impair fertility, thereby enhancing the chances of conception and preventing permanent infertility. For instance, in April 2023, according to the World Health Organization, a Switzerland-based intergovernmental organization, approximately 17.5% of the global adult population, or about 1 in 6 individuals, face infertility. Therefore, the increasing prevalence of infertility drives the growth of the female infertility industry.

Key Players In The Global Female Infertility Market

Major companies operating in the female infertility market are Pfizer Inc, Merck And Co Inc, Mayo Clinic, Teva Pharmaceutical Industries Ltd, Organon Theramex, Juniper Reproductive Health Ltd, Ferring Pharmaceuticals, Mankind Pharma, ARMC IVF, Zydus Cadila Healthcare, IBSA Institut Biochimique, Oxolife, Ava AG, Merck KGaA, Gedeon Richter Plc, Novartis AG, AbbVie Inc, Ipsen, Theramex, Vitrolife AB, Conceivable Life Sciences, AIVF

Global Female Infertility Market Trends and Insights

Major companies operating in the female infertility market are focusing on developing innovative products, such as non-invasive diagnostic tests, to gain a competitive edge in the industry. A noninvasive diagnostic test is a medical test that detects conditions or diseases without requiring surgery or penetration of the body. For instance, in August 2024, Heranova Lifesciences, a US-based biotech company, launched an early access program for HerResolve, a non-invasive diagnostic test for endometriosis. Endometriosis affects about 200 million women worldwide, causing symptoms like infertility, pain, and bleeding. For many women, an accurate diagnosis takes an average of 7-10 years from the onset of symptoms, mainly due to the varied symptom presentation and the invasive nature of the most reliable diagnostic method, exploratory laparoscopic surgery. HerResolve potentially reduces this diagnostic delay from years to months, leading to better patient and healthcare outcomes. HerResolve aims to shorten this timeline significantly, improving patient care and outcomes.

What Are Latest Mergers And Acquisitions In The Female Infertility Market?

In April 2023, CCRM Fertility, a US-based fertility clinic network, acquired the New Hope Center for Reproductive Medicine for an undisclosed amount. With this acquisition, CCRM expands fertility's presence on the East Coast, providing easier access to top-tier fertility care, advanced testing, state-of-the-art labs, and in-house genetics and research, ensuring leading success rates. The New Hope Center for Reproductive Medicine is a US-based fertility clinic that offers a range of services, including in vitro fertilization (IVF) to overcome female infertility.

Regional Outlook

Europe was the largest region in the female infertility market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Female Infertility Market?

The female infertility market consists of revenues earned by entities by providing services such as hormonal therapy and treatment, genetic testing and counseling, ovulation induction, egg and sperm donation and intrauterine insemination. The market value includes the value of related goods sold by the service provider or included within the service offering. The female infertility market also includes sales of fertility drugs, ovulation test kits, fertility supplements, insemination devices and ultrasound machines for fertility monitoring. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Female Infertility Market Report 2026?

The female infertility market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the female infertility industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.